Press Releases
- Phase 3 Study Presented at World Ophthalmology Congress Evaluates Investigational Use of Macugen in Patients with Diabetic Macular Edema June 5, 2010
- LEVEL Study Published in British Journal of Ophthalmology Evaluates Macugen as Maintenance Treatment for Patients with Neovascular Age-Related Macular Degeneration May 18, 2010
- Study Published in the American Journal of Ophthalmology Examines Investigational Use of Macugen in Patients with Branch Retinal Vein Occlusion (BRVO) January 29, 2010
- Study on the Investigational Use of Macugen in Patients with Diabetic Retinopathy Published in the British Journal of Ophthalmology October 21, 2010
DISCLOSURE NOTICE: The information contained in these press releases is current as of the date of publication. Eyetech assumes no obligation to update forward-looking statements contained in press releases as the result of new information or future events or developments.
Macugen® (pegaptanib sodium injection) is indicated for the treatment of neovascular age-related macular degeneration.
Important Safety Information
MACUGEN is contraindicated in patients with ocular or periocular infections or with known hypersensitivity to pegaptanib sodium or any other excipient in this product.
Safety or efficacy of MACUGEN beyond 2 years has not been demonstrated.
Intravitreal injections including those with MACUGEN have been associated with endophthalmitis. Proper aseptic injection technique—which includes use of sterile gloves, a sterile drape, and a sterile eyelid speculum (or equivalent)—should always be utilized when administering MACUGEN. In addition, patients should be monitored during the week following the injection to permit early treatment, should an infection occur.
Increases in intraocular pressure (IOP) have been seen within 30 minutes of injection with MACUGEN. Therefore, IOP as well as the perfusion of the optic nerve head should be monitored and managed appropriately.
Rare cases of anaphylaxis/anaphylactoid reactions, including angioedema, have been reported in postmarketing experience following the intravitreal administration procedure.
Serious adverse events related to the injection procedure occurring in <1% of intravitreal injections included endophthalmitis, retinal detachment, and iatrogenic traumatic cataract.
Most frequently reported adverse events in patients treated for up to 2 years were anterior chamber inflammation, blurred vision, cataract, conjunctival hemorrhage, corneal edema, eye discharge, eye irritation, eye pain, hypertension, increased IOP, ocular discomfort, punctate keratitis, reduced visual acuity, visual disturbance, vitreous floaters, and vitreous opacities. These events occurred in approximately 10% to 40% of patients.